

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO ANTIBODY-DRUG CONJUGATE DISCOVERY
COLLABORATION AGREEMENT WITH BOOSTIMMUNE, INC.

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Nona Biosciences (Suzhou) Co., Ltd (“**Nona Biosciences**”), a subsidiary wholly-owned by the Company, and Boostimmune, Inc. (“**Boostimmune**”) have entered into an antibody-drug conjugate (“**ADC**”) discovery collaboration agreement (the “**Agreement**”) as a strategic partnership to develop ADC therapy. Pursuant to the Agreement, Nona Biosciences shall provide its two light and two heavy chain (H2L2) Harbour Mice[®] platform for Boostimmune to develop ADC therapies against novel targets.

The collaboration marks a milestone for the Group as Nona Biosciences expands the Group’s collaboration network with global strategic perspective. It also represents industry recognition of the Group’s proprietary platform and antibody discovery capabilities. The Company believes that the Harbour Mice[®] platform together with the Group’s accumulated extensive experience in innovative biologics drug discovery can generate differentiated therapeutic molecules benefiting patients worldwide.

About Harbour Mice[®] platform

The Harbour Mice[®] platform generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE[®]) are capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice[®], HBICE[®] with single B cell cloning platform, the antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies.

About Boostimmune, Inc.

Boostimmune is a biotech company developing innovative, first-in-class antibody-based therapies to address unmet needs in oncology. Its pipeline projects consist of naked monoclonal antibodies to modulate the tumor immune microenvironment, ADCs to novel targets with potential patient selection biomarkers and an ISAC (Immune Stimulator Antibody Conjugate) directly targeting immunosuppressive myeloid cells.

Cautionary Statement: We cannot guarantee that we will be able to develop, or ultimately market, products under the Agreement successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 27 February 2024

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Mr. Ka Chi Yau and Dr. Albert R. Collinson as independent non-executive Directors.